CDRD is Canada’s national life sciences venture, powering the country’s life sciences industry by creating and growing companies of scale – while training the scientific and business talent needed to drive them to become leading global anchors for Canada.
We build collaborations with the very best partners from academia, industry, patient foundations, the investment community, and other Key Opinion Leaders to provide the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector — and ultimately into new therapies for patients.
Scroll down to find out how we do this...
Build New Companies of Scale
We work with investors, industry, and academia to proactively evaluate commercial opportunities, identify and advance promising technologies & platforms, and build compelling business cases and teams.
Scale-Up Existing Companies
We support Canadian SMEs by providing tailored access to world-class drug development infrastructure & commercialization/business experts to define and execute critical experiments that will maximize probability of future clinical success and attract capital.
Train Highly-Qualified Personnel
We offer three distinct & dedicated streams through The CDRD Academy: Executive Institute, Post-Graduate Institute & Undergraduate Institute.
Canadian Life Sciences Leaders Come Together to Discuss and Support Recommendations within the Federal Government’s Health and Biosciences Economic Strategy Table ReportOctober 25, 2018
To exemplify the collaborative spirit and leadership needed to advance the Canadian health and biosciences sector, Canadian life sciences leaders – CDRD, LifeSciences BC, TRIUMF Innovations and BIOTECanada – are hosting an event today to build support and encourage action and agreement that will...Read MoreCDRD re-organizes to align with key functions and optimize...Read More
CDRD re-organizes to align with key functions and optimize its role as Canada’s life sciences ventureOctober 22, 2018
Through this new structure, CDRD will be even stronger, and seek to realize our vision of Canadian life sciences leading the world....Read MoreCDRD Appoints Didier Leconte to its Board of DirectorsRead MoreCanadian Life Sciences Leaders Come Together to Discuss and...Read More
October 15, 2018
Didier is at the forefront of life sciences investment in Canada, working with the Fonds de solidarité FTQ on a mission that is perfectly aligned with CDRD’s, to contribute to Québec's and Canada’s economic growth by creating jobs through investments in small and medium-sized businesses, helping...Read MoreCDRD to be Presented with the BIOTECanada Gold Leaf...Read MoreCDRD re-organizes to align with key functions and optimize...Read More
September 26, 2018
The award recognizes CDRD’s contributions and impact as Canada’s national life sciences venture, bringing together national and international partners to be a catalyst for Canadian life sciences leading the world; and powering the country’s industry by creating and growing companies of scale while training the scientific...Read MoreCatching the FutureRead MoreCDRD Appoints Didier Leconte to its Board of DirectorsRead More
September 13, 2018
CDRD and BIOTECanada invite you to a thought-provoking evening to experience the change unfolding in real time....Read MoreCDRD Academy Announces Inaugural Cohort in Unique New...Read MoreCDRD to be Presented with the BIOTECanada Gold Leaf...Read More
September 6, 2018
Vancouver, Canada: CDRD – The Centre for Drug Research and Development, Canada’s national life sciences venture, is pleased to announce the first cohort of the CDRD Academy’s Executive Institute. Earlier this year, CDRD and Pfizer Canada announced the launch of the Executive Institute under the umbrella...Read MoreCDRD provides critical antibody engineering expertiseRead MoreCatching the FutureRead More
July 24, 2018
Dr. Peter Bergqvist describes how some of his work contributed to a recent commercial outcome with UBC and TxCell...Read MoreSpring/Summer 2018 CommuniqueRead MoreCDRD Academy Announces Inaugural Cohort in Unique New...Read More
July 23, 2018
Here's a quick snapshot update of recent events, activities and news from CDRD!...Read MoreCDRD & Schrödinger Announce Oncology Collaboration to...Read MoreCDRD provides critical antibody engineering expertiseRead More
May 30, 2018
CDRD will provide a portfolio of targeted antibodies and Schrödinger will apply its advanced computation platform in order to prioritize these drug candidates and otherwise accelerate discovery. The initial project will involve an immune checkpoint target that is present on cancer stem cells....Read MoreCDRD Further Builds Company Creation Team, Appoints Sacha...Read MoreSpring/Summer 2018 CommuniqueRead More
May 15, 2018
As an Entrepreneur-in-Residence, Sacha Mann will work with CDRD leadership to identify specific areas of strategic commercial opportunity, and then in partnership with other stakeholders, drive the building of a new company of scale that can develop those opportunities, and grow into a strong new anchor...Read MoreCDRD & Schrödinger Announce Oncology Collaboration to...Read More
See what else is new
Sepset Biosciences is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of...Read the article
Zucara is now moving forward with GLP toxicology, GMP manufacturing and other Investigational New Drug/Clinical Trial Application enabling activities to bring...Read the article
Outcomes with Impact
September 19, 2017
CDRD is committed to training the next generation of highly-qualified personnel to drive the development of innovations. Hear more about our unique Training Program and the opportunities it is creating from some of our young scientists…....Read MoreNovel therapies advancedRead More
August 24, 2017
CDRD has advanced 66 potential novel drug therapies towards the clinic. Many more are in production....Read MoreCommercial transactionsRead MoreTraining the Next GenerationRead More
August 11, 2017
CDRD has completed 14 commercial transactions including the merger of CDRD spin-off company, Kairos Therapeutics, with BC-based Zymeworks Inc. and creating one of Canada’s leading biotherapeutics companies....Read MoreSpin-off CompaniesRead MoreNovel therapies advancedRead More
August 11, 2017
CDRD has successfully created 7 spin-off companies including Kairos Therapeutics, Sitka Biopharma, Zucara Therapeutics, Precision Nanosystems, Immcure Therapeutics, Mesentech and Sepset Biopharma....Read MoreCommercial transactionsRead More
See what else is new
Working with CDRD
Academic discovery is the watering hole of innovation, but developing discoveries into new therapeutic products is a challenging process that requires complementary expertise, infrastructure and resources not typically available to an investigator. That's where CDRD comes in.
Whether a company is looking to accelerate development of their lead program or strengthen their pipeline by pulling a secondary program off the back-burner, CDRD provides solutions for whatever scientific and/or commercial roadblocks are impeding progress towards the next corporate value-creation point.